Xenon Pharmaceuticals PE Ratio 2012-2022 | XENE
Current and historical p/e ratio for Xenon Pharmaceuticals (XENE) from 2012 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Xenon Pharmaceuticals PE ratio as of January 31, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Xenon Pharmaceuticals PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-01-31 |
39.09 |
|
0.00 |
| 2022-09-30 |
36.10 |
$-2.04 |
0.00 |
| 2022-06-30 |
30.42 |
$-1.83 |
0.00 |
| 2022-03-31 |
30.57 |
$-1.79 |
0.00 |
| 2021-12-31 |
31.24 |
$-1.86 |
0.00 |
| 2021-09-30 |
15.28 |
$-1.63 |
0.00 |
| 2021-06-30 |
18.62 |
$-1.52 |
0.00 |
| 2021-03-31 |
17.90 |
$-1.01 |
0.00 |
| 2020-12-31 |
15.38 |
$-0.81 |
0.00 |
| 2020-09-30 |
11.07 |
$-0.89 |
0.00 |
| 2020-06-30 |
12.54 |
$-0.97 |
0.00 |
| 2020-03-31 |
11.34 |
$-1.34 |
0.00 |
| 2019-12-31 |
13.11 |
$-1.54 |
0.00 |
| 2019-09-30 |
9.01 |
$-1.41 |
0.00 |
| 2019-06-30 |
9.86 |
$-1.71 |
0.00 |
| 2019-03-31 |
10.16 |
$-1.79 |
0.00 |
| 2018-12-31 |
6.31 |
$-1.58 |
0.00 |
| 2018-09-30 |
13.20 |
$-1.72 |
0.00 |
| 2018-06-30 |
9.20 |
$-1.50 |
0.00 |
| 2018-03-31 |
4.90 |
$-1.48 |
0.00 |
| 2017-09-30 |
2.95 |
$-1.59 |
0.00 |
| 2017-06-30 |
3.15 |
$-1.67 |
0.00 |
| 2017-03-31 |
4.00 |
$-1.68 |
0.00 |
| 2016-12-31 |
7.70 |
$-1.48 |
0.00 |
| 2016-09-30 |
8.10 |
$-1.43 |
0.00 |
| 2016-06-30 |
5.90 |
$-1.19 |
0.00 |
| 2016-03-31 |
6.99 |
$-0.84 |
0.00 |
| 2015-12-31 |
8.04 |
$-0.91 |
0.00 |
| 2015-09-30 |
8.26 |
$0.93 |
8.88 |
| 2015-06-30 |
11.53 |
$0.75 |
15.37 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.377B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
